Moreover, assessing the combinatorial efficacyof CU06-1004 with standard-of-care biologics (e.g., anti-TNF agents) or immune checkpoint inhibitors is paramount, as supported by recent evidence on combination therapy in IBD (Dai et al., 2023). This evidence concerns the gene TNF and inflammatory bowel disease.